123 related articles for article (PubMed ID: 9005288)
21. Genetic testing for breast cancer susceptibility: frequency of BRCA1 and BRCA2 mutations.
Ganguly A; Leahy K; Marshall AM; Dhulipala R; Godmilow L; Ganguly T
Genet Test; 1997; 1(2):85-90. PubMed ID: 10464631
[TBL] [Abstract][Full Text] [Related]
22. Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer.
Schorge JO; Mahoney NM; Miller DS; Coleman RL; Muller CY; Euhus DM; Tomlinson GE
Gynecol Oncol; 2001 Nov; 83(2):383-7. PubMed ID: 11606101
[TBL] [Abstract][Full Text] [Related]
23. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer.
Warner E; Foulkes W; Goodwin P; Meschino W; Blondal J; Paterson C; Ozcelik H; Goss P; Allingham-Hawkins D; Hamel N; Di Prospero L; Contiga V; Serruya C; Klein M; Moslehi R; Honeyford J; Liede A; Glendon G; Brunet JS; Narod S
J Natl Cancer Inst; 1999 Jul; 91(14):1241-7. PubMed ID: 10413426
[TBL] [Abstract][Full Text] [Related]
24. Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.
Rosenthal E; Moyes K; Arnell C; Evans B; Wenstrup RJ
Breast Cancer Res Treat; 2015 Jan; 149(1):223-7. PubMed ID: 25476495
[TBL] [Abstract][Full Text] [Related]
25. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history.
Berry DA; Parmigiani G; Sanchez J; Schildkraut J; Winer E
J Natl Cancer Inst; 1997 Feb; 89(3):227-38. PubMed ID: 9017003
[TBL] [Abstract][Full Text] [Related]
26. Role of genetic factors in breast cancer susceptibility.
Børresen AL
Acta Oncol; 1992; 31(2):151-5. PubMed ID: 1622629
[TBL] [Abstract][Full Text] [Related]
27. BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and ovarian cancer.
Schubert EL; Mefford HC; Dann JL; Argonza RH; Hull J; King MC
Genet Test; 1997; 1(1):41-6. PubMed ID: 10464624
[TBL] [Abstract][Full Text] [Related]
28. Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.
Stadler ZK; Saloustros E; Hansen NA; Schluger AE; Kauff ND; Offit K; Robson ME
Breast Cancer Res Treat; 2010 Sep; 123(2):581-5. PubMed ID: 20221693
[TBL] [Abstract][Full Text] [Related]
29. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.
Martin AM; Blackwood MA; Antin-Ozerkis D; Shih HA; Calzone K; Colligon TA; Seal S; Collins N; Stratton MR; Weber BL; Nathanson KL
J Clin Oncol; 2001 Apr; 19(8):2247-53. PubMed ID: 11304778
[TBL] [Abstract][Full Text] [Related]
30. Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients.
Crawford B; Adams SB; Sittler T; van den Akker J; Chan S; Leitner O; Ryan L; Gil E; van 't Veer L
Breast Cancer Res Treat; 2017 Jun; 163(2):383-390. PubMed ID: 28281021
[TBL] [Abstract][Full Text] [Related]
31. Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer.
Shiri-Sverdlov R; Oefner P; Green L; Baruch RG; Wagner T; Kruglikova A; Haitchick S; Hofstra RM; Papa MZ; Mulder I; Rizel S; Bar Sade RB; Dagan E; Abdeen Z; Goldman B; Friedman E
Hum Mutat; 2000 Dec; 16(6):491-501. PubMed ID: 11102978
[TBL] [Abstract][Full Text] [Related]
32. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
[TBL] [Abstract][Full Text] [Related]
33. Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes.
Vehmanen P; Friedman LS; Eerola H; McClure M; Ward B; Sarantaus L; Kainu T; Syrjäkoski K; Pyrhönen S; Kallioniemi OP; Muhonen T; Luce M; Frank TS; Nevanlinna H
Hum Mol Genet; 1997 Dec; 6(13):2309-15. PubMed ID: 9361038
[TBL] [Abstract][Full Text] [Related]
34. Hereditary breast cancer: part I. Diagnosing hereditary breast cancer syndromes.
Lynch HT; Silva E; Snyder C; Lynch JF
Breast J; 2008; 14(1):3-13. PubMed ID: 18086272
[TBL] [Abstract][Full Text] [Related]
35. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.
Roa BB; Boyd AA; Volcik K; Richards CS
Nat Genet; 1996 Oct; 14(2):185-7. PubMed ID: 8841191
[TBL] [Abstract][Full Text] [Related]
36. Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA1 gene.
Ticha I; Kleibl Z; Stribrna J; Kotlas J; Zimovjanova M; Mateju M; Zikan M; Pohlreich P
Breast Cancer Res Treat; 2010 Nov; 124(2):337-47. PubMed ID: 20135348
[TBL] [Abstract][Full Text] [Related]
37. Elevated frequency and functional activity of a specific germ-line p53 intron mutation in familial breast cancer.
Lehman TA; Haffty BG; Carbone CJ; Bishop LR; Gumbs AA; Krishnan S; Shields PG; Modali R; Turner BC
Cancer Res; 2000 Feb; 60(4):1062-9. PubMed ID: 10706125
[TBL] [Abstract][Full Text] [Related]
38. Hereditary breast and ovarian cancer in Asia: genetic epidemiology of BRCA1 and BRCA2.
Liede A; Narod SA
Hum Mutat; 2002 Dec; 20(6):413-24. PubMed ID: 12442265
[TBL] [Abstract][Full Text] [Related]
39. A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families.
Phelan CM; Kwan E; Jack E; Li S; Morgan C; Aubé J; Hanna D; Narod SA
Hum Mutat; 2002 Nov; 20(5):352-7. PubMed ID: 12402332
[TBL] [Abstract][Full Text] [Related]
40. [Familial breast cancer, ovarian cancer].
Inoue M
Nihon Rinsho; 2006 Jun; Suppl 2():366-70. PubMed ID: 16817423
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
